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What\'s new?The onset 3 trial evaluated the efficacy and safety of adding mealtime fast‐acting insulin aspart to basal insulin in people with Type 2 diabetes.This *post hoc* analysis of onset 3 indicates that low 1,5‐anhydroglucitol is predictive of basal--bolus treatment effect.The findings suggest that 1,5‐anhydroglucitol measurements may be useful for identifying people with Type 2 diabetes who would most benefit from intensifying insulin therapy, but further research is needed to determine whether 1,5‐anhydroglucitol adds clinical utility beyond that of HbA~1c~.

Introduction {#dme13693-sec-0006}
============

Type 2 diabetes is characterized by insulin resistance and impaired insulin secretion, resulting in both fasting and postprandial hyperglycaemia. To control fasting plasma glucose (FPG), treatment guidelines recommend initiating basal insulin when HbA~1c~ targets have not been achieved with oral antidiabetes drugs [1](#dme13693-bib-0001){ref-type="ref"}. While control of FPG is necessary, it is usually insufficient for maintaining appropriate HbA~1c~ targets [2](#dme13693-bib-0002){ref-type="ref"}, and many people with Type 2 diabetes will eventually benefit from treatment intensification with drugs that target postprandial plasma glucose (PPG) excursions (e.g. mealtime bolus insulin or glucagon‐like peptide‐1 receptor analogues). However, determining which people with Type 2 diabetes would benefit from basal--bolus therapy is a challenge facing physicians in clinical practice.

Plasma 1,5‐anhydroglucitol (1,5‐AG) has been proposed as a marker to assess short‐term glycaemic control in people with Type 1 and Type 2 diabetes [3](#dme13693-bib-0003){ref-type="ref"}, [4](#dme13693-bib-0004){ref-type="ref"}, [5](#dme13693-bib-0005){ref-type="ref"}. 1,5‐AG is an endogenous dietary polyol, structurally similar to glucose, that is maintained at a constant steady state in the blood [6](#dme13693-bib-0006){ref-type="ref"}. When blood glucose is in the normal range, 1,5‐AG is reabsorbed in the proximal tubules of the kidney and is stable in the range of 6.8--29.3 μg/ml in women and 10.7--32.0 μg/ml in men [4](#dme13693-bib-0004){ref-type="ref"}. When blood glucose exceeds the renal threshold (\~180 mg/dl), glucose blocks reabsorption of 1,5‐AG and circulating levels decrease. When glycaemic control is restored, 1,5‐AG levels recover at a rate of \~0.3 μg/ml per day. Consequently, 1,5‐AG responds rapidly to changes in blood glucose, and, in contrast to HbA~1c~, can reflect glycaemic control over the previous 1--2 weeks [7](#dme13693-bib-0007){ref-type="ref"}, [8](#dme13693-bib-0008){ref-type="ref"}.

The onset 3 trial was an 18‐week, multicentre, open‐label, randomized phase 3 trial that evaluated the efficacy and safety of fast‐acting insulin aspart (faster aspart) in basal--bolus therapy vs. basal insulin‐only therapy in people with Type 2 diabetes [9](#dme13693-bib-0009){ref-type="ref"}. Faster aspart is a new formulation of insulin aspart that presents with an earlier onset of appearance, a higher early insulin exposure, and a greater early glucose‐lowering effect compared with conventional insulin aspart [10](#dme13693-bib-0010){ref-type="ref"}. In onset 3, as part of basal--bolus therapy, faster aspart significantly reduced HbA~1c~ compared with basal insulin \[estimated treatment difference (ETD) 95% confidence interval (CI)\]: −0.94% \[−1.17; −0.72\]; *P* \<0.0001. The reduction in overall mean 2‐h PPG and mean PPG increment for all meals \[derived from self‐measured plasma glucose (SMPG) values\], and the increase in 1,5‐AG were also statistically significant in favour of basal--bolus therapy compared with basal insulin‐only therapy [9](#dme13693-bib-0009){ref-type="ref"}.

In the current analysis, it was hypothesized that the treatment effect of basal--bolus therapy would be different in people with Type 2 diabetes and low baseline 1,5‐AG compared with people with Type 2 diabetes and high baseline 1,5‐AG (i.e. that baseline 1,5‐AG would be predictive of the basal--bolus treatment effect). This hypothesis was explored using data from onset 3 to perform a *post hoc* analysis of the treatment differences within subgroups based on baseline 1,5‐AG.

Participants and methods {#dme13693-sec-0007}
========================

onset 3 design {#dme13693-sec-0008}
--------------

The onset 3 methodology has been reported previously [9](#dme13693-bib-0009){ref-type="ref"}. The trial compared intensification with faster aspart in a basal--bolus regimen vs. continued basal insulin therapy, both in combination with metformin, in participants aged ≥18 years with a BMI ≤40.0 kg/m^2^ diagnosed with Type 2 diabetes for ≥6 months and treated for ≥3 months prior to screening with once‐daily basal insulin \[insulin detemir, insulin glargine U100 or neutral protamine Hagedorn (NPH)\] and metformin ≥1000 mg with or without other oral antidiabetes drugs. Participants had an HbA~1c~ of 59--80 mmol/mol (7.5--9.5%) if taking metformin, or 59--75 mmol/mol (7.5--9.0%) if taking metformin plus other oral antidiabetes drugs at the screening visit.

At the start of an 8‐week run‐in period, participants continued their once‐daily basal insulin and metformin and discontinued all other oral antidiabetes drugs. During run‐in, basal insulin dose was optimized using a treat‐to‐target approach, with weekly adjustments to a pre‐breakfast target of 4.0--6.0 mmol/l (71--108 mg/dl). After the run‐in period, basal insulin dose was adjusted at the investigator\'s discretion.

Participants requiring further intensification \[i.e. HbA~1c~ 53--75 mmol/mol (7.0--9.0%) following the run‐in period\] were randomized 1:1 to faster aspart in basal--bolus therapy or to continue basal insulin‐only therapy. Randomization was stratified based on the type of basal insulin used (insulin detemir, insulin glargine U100 or NPH). Participants randomized to receive faster aspart self‐adjusted the dose by 1‐unit increments aiming for a pre‐prandial or bedtime target of 4.0--6.0 mmol/l (71--108 mg/dl).

*Post hoc* analysis population and outcomes {#dme13693-sec-0009}
-------------------------------------------

All participants included in the full analysis set were considered for the *post hoc* analysis. Participants were required to have baseline 1,5‐AG information available for inclusion (baseline was defined as the randomization visit after basal insulin optimization). As 1,5‐AG levels can display substantial variation between individuals, participants were divided into subgroups based on a range of 1,5‐AG cut‐off values (2, 3, 4, 5 or 6 μg/ml). Treatment differences in change from baseline in HbA~1c~ were estimated for 1,5‐AG subgroups below and above each cut‐off value.

Statistical analysis {#dme13693-sec-0010}
--------------------

Change from baseline in HbA~1c~ in subgroups above and below each 1,5‐AG cut‐off value was analyzed using a mixed‐effects model for repeated measures (MMRM). All calculated changes in HbA~1c~ from baseline at weeks 6, 12 and 18 were included in the analysis. The model included a treatment‐by‐subgroup interaction, alongside the main effects of treatment, subgroup (above/below cut‐off value), region (Asia, Europe, North America or South America) and strata (insulin detemir, insulin glargine U100 or NPH), with baseline HbA~1c~ and baseline 1,5‐AG as covariates. All effects were nested within visit; an unstructured covariance matrix was used to describe the variability for the repeated measurements for participants. The *P*‐value for the interaction term was used to evaluate if the treatment effect was different above vs. below the cut‐off value. A *P*‐value \<0.05 was considered statistically significant.

Results {#dme13693-sec-0011}
=======

Baseline characteristics {#dme13693-sec-0012}
------------------------

Baseline characteristics in the onset 3 population were similar between the basal--bolus therapy and basal insulin‐only treatment groups (Table[1](#dme13693-tbl-0001){ref-type="table"}) [9](#dme13693-bib-0009){ref-type="ref"}. 42.4% (n = 100) of participants were from Europe or North America. Of the onset 3 population (n = 236), 234 participants had baseline 1,5‐AG information available and were included in the *post hoc* analysis of baseline characteristics (Table [2](#dme13693-tbl-0002){ref-type="table"}). Only participants with post‐baseline HbA~1c~ data contributed to the MMRM analysis (n = 232).

###### 

Baseline characteristics of the onset 3 population at randomization [9](#dme13693-bib-0009){ref-type="ref"}

  Characteristic, n, FAS        Faster aspart in basal--bolus therapy (n = 116)      Basal insulin‐only therapy (n = 120)               Total (n = 236)
  ----------------------------- ---------------------------------------------------- -------------------------------------------------- -----------------
  Age, years                    57.5 (9.9)                                           57.4 (8.5)                                         57.4 (9.2)
  Gender, n (%)                                                                                                                         
  Men                           55 (47.4)                                            59 (49.2)                                          114 (48.3)
  Women                         61 (52.6)                                            61 (50.8)                                          122 (51.7)
  BMI, kg/m^2^                  30.4 (5.0)                                           31.1 (4.7)                                         30.8 (4.8)
  Body weight, kg               82.2 (16.2)                                          85.1 (17.3)                                        83.7 (16.8)
  Duration of diabetes, years   10.9[\*](#dme13693-note-0003){ref-type="fn"} (6.1)   11.8 (7.4)                                         11.3 (6.3)
  HbA~1c~                                                                                                                               
  mmol/mol                      63 (8)                                               63 (7)                                             63 (8)
  \%                            7.9 (0.7)                                            7.9 (0.7)                                          7.9 (0.7)
  FPG                                                                                                                                   
  mmol/l                        7.4 (2.4)                                            7.7[†](#dme13693-note-0003){ref-type="fn"} (2.9)   7.5 (2.6)
  mg/dl                         132.5 (43.5)                                         138.9 (51.4)                                       135.7 (47.7)
  1,5‐AG, μg/ml                 8.2 (5.4)                                            7.7 (4.7)                                          7.9 (5.0)

Data are mean (SD) unless stated otherwise.

\*n = 115; †n = 119.

The conversion factor used for glucose between mmol/l and mg/dl was 0.0555.

1,5‐AG, 1,5‐anhydroglucitol; FAS, full analysis set; faster aspart, fast‐acting insulin aspart; FPG, fasting plasma glucose; n, number of participants contributing to the analysis.

Reproduced and adapted from, with permission from John Wiley and Sons, Rodbard HW *et al*. *Diabetes Obes Metab* 2017; 19: 1389--1396. © John Wiley and Sons 2017.

John Wiley & Sons, Ltd

###### 

Baseline characteristics of participants included in the *post hoc* analysis by baseline 1,5‐AG ≤3 μg/ml and \>3 μg/ml

  Characteristic                Baseline 1,5‐AG ≤3 μg/ml   Baseline 1,5‐AG \>3 μg/ml                                                
  ----------------------------- -------------------------- --------------------------- -------------- -------------- -------------- --------------
  Age, years                    52.2 (10.1)                53.9 (7.4)                  52.9 (8.9)     58.5 (9.6)     57.9 (8.3)     58.2 (8.9)
  Gender, % men                 63.2                       56.3                        60.0           44.3           48.0           46.2
  Body weight, kg               85.3 (17.3)                80.3 (15.6)                 83.0 (16.5)    81.5 (16.0)    85.8 (17.6)    83.7 (16.9)
  BMI, kg/m^2^                  29.9 (3.8)                 29.6 (5.4)                  29.8 (4.5)     30.5 (5.2)     31.3 (4.5)     30.9 (4.9)
  Duration of diabetes, years   11.6 (5.2)                 11.9 (7.6)                  11.7 (6.3)     10.7 (6.3)     11.9 (7.4)     11.3 (6.9)
  HbA~1c~                                                                                                                           
  mmol/mol                      68 (10)                    68 (7)                      68 (8)         62 (7)         63 (7)         62 (7)
  \%                            8.4 (0.9)                  8.3 (0.7)                   8.4 (0.8)      7.9 (0.6)      7.9 (0.7)      7.9 (0.6)
  FPG                                                                                                                               
  mmol/l                        8.0 (2.8)                  8.4 (2.5)                   8.2 (2.7)      7.2 (2.3)      7.6 (2.9)      7.4 (2.7)
  mg/dl                         144.3 (50.3)               151.9 (45.8)                147.7 (47.7)   130.1 (42.0)   137.1 (52.6)   133.7 (47.7)
  2‐h PPG (SMPG)                                                                                                                    
  mmol/l                        9.8 (2.1)                  9.9 (2.1)                   9.8 (2.0)      8.5 (1.8)      8.8 (1.7)      8.7 (1.7)
  mg/dl                         176.6 (37.8)               178.4 (37.8)                176.6 (36.0)   153.2 (32.4)   158.6 (30.6)   156.8 (30.6)
  1,5‐AG, μg/ml                 2.2 (0.6)                  2.1 (0.4)                   2.1 (0.5)      9.3 (5.1)      8.6 (4.4)      9.0 (4.8)

Data are mean (SD) unless stated otherwise.

The conversion factor used for glucose between mmol/l and mg/dl was 0.0555.

Of the onset 3 population (n = 236), 234 participants had baseline 1,5‐AG information available and were included in the *post hoc* analysis.

1,5‐AG, 1,5‐anhydroglucitol; faster aspart, fast‐acting insulin aspart; FPG, fasting plasma glucose; n, number of patients contributing to the analysis; PPG, postprandial plasma glucose; SMPG, self‐measured plasma glucose.

John Wiley & Sons, Ltd

Association between baseline 1,5‐AG and change from baseline in HbA~1c~ after 18 weeks of treatment {#dme13693-sec-0013}
---------------------------------------------------------------------------------------------------

Figure [1](#dme13693-fig-0001){ref-type="fig"} indicates a separation in HbA~1c~ treatment difference at week 18 between basal--bolus therapy and basal insulin‐only therapy at lower baseline 1,5‐AG values. The difference between the smoothing curves fitted to the scatter plot demonstrates the larger treatment effect at lower baseline 1,5‐AG compared with higher baseline 1,5‐AG.

![Scatter plot of change from baseline in HbA~1c~ after 18 weeks of randomized treatment against baseline 1,5‐AG.\
Penalized B‐spline scatter plot smoothing is used to depict the association between change from baseline in HbA~1c~ and baseline 1,5‐AG.\
1,5‐AG, 1,5‐anhydroglucitol; faster aspart, fast‐acting insulin aspart.](DME-35-1273-g001){#dme13693-fig-0001}

HbA~1c~ treatment difference above vs. below 1,5‐AG cut‐off values {#dme13693-sec-0014}
------------------------------------------------------------------

The ETD in change from baseline in HbA~1c~ between basal--bolus therapy and basal insulin‐only therapy was statistically significantly greater in participants with baseline 1,5‐AG ≤3 μg/ml (n = 34) vs. \>3 μg/ml (n = 198) \[ETD (95% CI): −1.53% (−2.12; −0.94) vs. −0.82% (−1.07; −0.57); *P‐*value for interaction = 0.03\]. The ETD became more pronounced when comparing participants with 1,5‐AG ≤2 μg/ml (n = 15) vs. \>2 μg/ml (n = 217) \[ETD (95% CI): −2.26% (−3.15; −1.36) vs. −0.85% (−1.08; −0.62); *P‐*value for interaction = 0.003\]. For cut‐off values ≥4 μg/ml, ETDs were numerically greater below the cut‐off compared with above, although the interaction terms were not statistically significant (Fig.[2](#dme13693-fig-0002){ref-type="fig"}).

![Estimated treatment difference in change from baseline in HbA~1c~ above and below different 1,5‐AG cut‐off values.\
Change from baseline in HbA~1c~ was analysed using an MMRM. The model included a treatment‐by‐subgroup interaction, alongside main effects of treatment, subgroup (above/below cut‐off value), region and strata, with baseline HbA~1c~ and baseline 1,5‐AG as covariates. *P*‐values for the interaction term were used to evaluate if the ETD was different above vs. below the cut‐off values. Only participants with post‐baseline HbA~1c~ data contributed to the MMRM analysis (n = 232).\
1,5‐AG, 1,5‐anhydroglucitol; CI, confidence interval; ETD, estimated treatment difference; MMRM, mixed‐effects model for repeated measures; n, number of participants contributing to the analysis.](DME-35-1273-g002){#dme13693-fig-0002}

Baseline characteristics above and below 1,5‐AG cut‐off values {#dme13693-sec-0015}
--------------------------------------------------------------

Baseline characteristics of participants in the 3 μg/ml 1,5‐AG cut‐off subgroups are shown in Table[2](#dme13693-tbl-0002){ref-type="table"}. Baseline characteristics were similar between basal--bolus therapy and basal insulin‐only therapy within the two subgroups. Participants in the ≤3 μg/ml subgroup had numerically higher mean HbA~1c~, FPG and 2‐h PPG (SMPG) at baseline compared with participants in the \>3 μg/ml subgroup \[≤3 (n = 35) vs. \>3 μg/ml (n = 199): HbA~1c~, 68 vs. 62 mmol/mol (8.4 vs. 7.9%); FPG, 8.2 vs. 7.4 mmol/l (147.7 vs. 133.7 mg/dl); 2‐h PPG (SMPG), 9.8 vs. 8.7 mmol/l (176.6 vs. 156.8 mg/dl)\]. Body weight, BMI and duration of diabetes were similar between the two subgroups. The baseline characteristics of participants in the 2, 4, 5 and 6 μg/ml cut‐off subgroups are included in the supporting information for this article (Table [S1](#dme13693-sup-0001){ref-type="supplementary-material"}).

Discussion {#dme13693-sec-0016}
==========

In onset 3, addition and titration of mealtime faster aspart in basal--bolus therapy effectively improved glycaemic control in people with Type 2 diabetes, demonstrating the expected superiority to basal insulin‐only therapy for HbA~1c~ and PPG control [9](#dme13693-bib-0009){ref-type="ref"}. However, in routine clinical practice, identifying people with Type 2 diabetes who could most benefit from intensifying treatment with basal--bolus therapy, and intensifying in a timely manner, is a challenge. Indeed, a recent study showed that only 30.9% of people with Type 2 diabetes with HbA~1c~ ≥59 mmol/mol (≥7.5%) on basal insulin had their treatment intensified after a median 3.7‐year delay [11](#dme13693-bib-0011){ref-type="ref"}.

This *post hoc* analysis of onset 3 suggests that participants with low baseline 1,5‐AG (≤3 μg/ml) experienced an increased benefit in HbA~1c~ reduction with basal--bolus therapy compared with participants with a higher baseline 1,5‐AG (\>3 μg/ml). Since all statistical models were adjusted for HbA~1c~ at baseline, the results can be interpreted as indicating that if two individuals have similar HbA~1c~ but one has a low 1,5‐AG then the latter may experience an increased benefit in HbA~1c~ reduction with basal--bolus therapy. It is important to note that this analysis does not address the question of whether 1,5‐AG or HbA~1c~ alone is more useful for predicting response to adding basal--bolus therapy. Instead, the results demonstrate, in a prospective setting, the complementary value of 1,5‐AG to HbA~1c~.

At baseline, participants in the 1,5‐AG ≤3 μg/ml subgroup had higher 2‐h PPG (SMPG) across all meals compared with participants in the 1,5‐AG \>3 μg/ml subgroup \[SMPG: 9.8 mmol/l (176.6 mg/dl) vs. 8.7 mmol/l (156.8 mg/dl)\]. While intensifying insulin therapy based on PPG values is recommended, obtaining information on the prandial component of hyperglycaemia requires frequently sampled blood glucose measurements and relies on patient cooperation. In contrast, 1,5‐AG reflects glycaemic control over the previous 1--2 weeks and is more convenient to measure than a full SMPG profile.

A previous *post hoc* analysis of people with Type 2 diabetes and suboptimal control with oral antidiabetes drugs \[HbA~1c~ 54--63 mmol/mol (7.1--7.9%)\] found that those with baseline 1,5‐AG \<7.8 μg/ml achieved greater HbA~1c~ reduction with initiation of insulin lispro mix 75/25 compared with insulin glargine [12](#dme13693-bib-0012){ref-type="ref"}. Although the study suggests that 1,5‐AG may offer therapeutic insight when starting insulin therapy, it did not find 1,5‐AG to be predictive of treatment effect.

While this is the first study to explore the use of 1,5‐AG as a predictor of the response to basal--bolus therapy, other studies have shown that 1,5‐AG is associated with the macro‐ and microvascular complications of diabetes. Analysis of samples from \~10 000 people in the 20‐year Atherosclerosis Risk in Communities study found that, after adjustment for HbA~1c~, 1,5‐AG was associated with retinopathy and chronic kidney disease in those with diagnosed diabetes [13](#dme13693-bib-0013){ref-type="ref"}. Additionally, people with diabetes and 1,5‐AG \<6.0 μg/ml had an increased risk of coronary heart disease, stroke, heart failure or death compared with people with 1,5‐AG ≥6 μg/ml and no history of diabetes [14](#dme13693-bib-0014){ref-type="ref"}.

A limitation of this *post hoc* analysis is the small number of participants in the baseline 1,5‐AG subgroups; this is reflected in the wide confidence intervals in the lower 1,5‐AG subgroups. In addition, due to its exploratory nature, the analysis cannot identify an optimal cut‐off value for 1,5‐AG for predicting response to basal--bolus therapy. Randomized clinical trials are needed to further evaluate 1,5‐AG as a useful predictor of response to therapies targeting PPG.

In conclusion, this *post hoc* analysis indicates that people with Type 2 diabetes and low 1,5‐AG have an added treatment benefit with basal--bolus therapy compared with those with higher 1,5‐AG. This suggests that 1,5‐AG may be useful in identifying subgroups of people for whom basal--bolus therapy is a particularly promising treatment option. However, an added advantage of basal--bolus therapy was observed only in a relatively small subgroup of participants with very low 1,5‐AG (≤3 μg/ml), and further research is needed to clarify the clinical utility of these findings.
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**Table S1.** Baseline characteristics of participants included in the *post hoc* analysis by baseline 1,5‐AG---cut‐off values of 2, 4, 5 and 6 μg/ml.

###### 

Click here for additional data file.
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